Citations

Showing 10 of 108162 citations.

Computer automation for physics chart check should be adopted in clinic to replace manual chart checking for radiotherapy
Clouser, Edward , Chen, Quan , Rong, Yi , Clouser, Edward L, Rong, Yi , Clouser, Edward Lee

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 5, 2021 | Volume: 22 | Issue: 2 | Pages: 4-8

10.1002/acm2.13177 | PMID 33529445 Get It

Chemotherapy‐based approach is the preferred treatment for sporadic late‐onset nemaline myopathy with a monoclonal protein
Kotchetkov, Rouslan , Susman, David , Bhutani, Divaya , Broch, Kaspar , Bhutani, Divaya , Dispenzieri, Angela , Buadi, Francis K.

Mayo Clinic

International Journal of Cancer | February 5, 2021 | Volume: 148 | Issue: 11 | Pages: 2807-2814

10.1002/ijc.33483 | PMID 33529362 Get It

Abstract Sporadic late‐onset nemaline myopathy (SLONM) associated with monoclonal protein (MP) is a rare disease with an aggressive, and often fatal course. Whether SLONM + MP represents a malignancy or dysimmune disease remains unclear. Currently, two main approaches are used to treat SLONM + MP: nonchemotherapy‐based treatment (immunosuppression, intravenous immunoglobulins, plasmapheresis and plasma exchange) or chemotherapy with or without autologous stem cell transplantation. Due to the rare occurrence of the disease, the best treatment modality is unknown. We analyzed treatment and outcomes in a large cohort of 53 patients with SLONM + MP: four our own patients and 49 cases from published literature. Neurological improvement in the nonchemotherapy group (N = 25) was observed in 52% of patients: 8% reached marked improvement, 8% moderate response, 36% mild response; none reached complete remission (CR). In the chemotherapy group (N = 28), neurological improvement was seen in 86% of patients: 46% reached CR, 25% marked response, 11% moderate response and 4% mild response. The best neurological improvement correlated with deep hematological remission. Mean time to best response in the chemotherapy group was 8 months versus 21 months in the nonchemotherapy group ( P < .001). Overall survival was higher in patients in the chemotherapy group. A chemotherapy approach should be the preferred treatment for patients with SLOMN + MP with the goal to reach complete hematologic remission. Based on the clinical, morphological peculiarities, aggressive disease course and superior clinical benefits of chemotherapy over nonchemotherapy, SLONM + MP should be considered as a hematological malignancy with the presence of MP of clinical rather than undetermined significance.
Expression defect of the rare variant/Brugada mutation R1512W depends upon the SCN5A splice variant background and can be rescued by mexiletine and the common polymorphism H558R
Hu, Rou-Mu, Song, E , Tester, David J. , Deschênes, Isabelle , Ackerman, Michael J. , Makielski, Jonathan C., Tan, Bi-Hua, Song, Evelyn J., Tan, Bi‐Hua

Mayo Clinic

Channels | February 5, 2021 | Volume: 15 | Issue: 1 | Pages: 253-261

10.1080/19336950.2021.1875645 | PMID 33535892 Get It

Can cryptogenic multifocal ulcerous stenosing enteritis (CMUSE) be diagnosed in a patient with non-steroidal anti-inflammatory drug exposure?
Osman, Karim T. , Maselli, Daniel B. , Mounajjed, Taofic, Mounajjed, Taofic M, Grotz, Travis E.

Mayo Clinic

BMJ Case Reports | February 4, 2021 | Volume: 14 | Issue: 2 | Pages: e238160

10.1136/bcr-2020-238160 | PMID 33542016 Get It

The differential diagnosis for ulcerating small bowel strictures is extensive and includes exposure to non-steroidal anti-inflammatory drugs (NSAIDs), Crohn’s disease, infections, gastrointestinal lymphoma and vasculopathy. It also encompasses the exceptionally rare and poorly understood diagnosis of cryptogenic multifocal ulcerative stenosing enterocolitis (CMUSE), often a diagnosis of exclusion and considerable difficulty. We present a case of persistent proximal jejunal ulcerating stenoses in a 75-year-old Caucasian man, which continued despite cessation of NSAIDs. After extensive clinical, radiographic, laboratory and ultimately surgical pathological appraisal—as well as failure to improve with both misoprostol and budesonide—he was diagnosed with CMUSE and managed with limited small bowel resection. In the presentation of this case, we aim to underscore the diagnostic challenges that clinicians face in differentiating CMUSE from other more common diagnoses, particularly NSAIDs-induced enteropathy.
Pharmacogenomics Education and Perceptions: is there A Gap Between Internal Medicine Resident and Attending Physicians?
Vitek, Carolyn R. Rohrer , Giri, Jyothsna , Caraballo, Pedro J. , Curry, Timothy B. , Nicholson, Wayne T. , Rohrer Vitek, Carolyn R , Caraballo, Pedro J

Mayo Clinic

Pharmacogenomics | February 4, 2021 | Volume: 22 | Issue: 4 | Pages: 195-201

10.2217/pgs-2020-0141 | PMID 33538610 Get It

Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of Helicobacter pylori and Genotypic Markers of Clarithromycin Resistance Directly from Stool
Rolón, Rebecca Marrero, Cunningham, Scott A. , Mandrekar, Jayawant N. , Polo, Erin T., Patel, Robin , Marrero Rolon, Rebecca, Patel, Robin , Cunningham, Scott A

Mayo Clinic

Journal of Clinical Microbiology | February 4, 2021 | Volume: 59 | Issue: 5 | Pages: No page available

10.1128/jcm.03040-20 | PMID 33536295 Get It

Helicobacter pylori infection is mainly diagnosed noninvasively, with susceptibility testing traditionally requiring endoscopy. Treatment is empirical, with clarithromycin-based triple therapy recommended where resistance rates are below 15%. Rising rates of clarithromycin resistance, resulting in high therapy failure rates, are seen worldwide, but U.S. data are limited.
Faculty Opinions recommendation of The loopometer: a quantitative in vivo assay for DNA-looping proteins.
Maher, Jim

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | February 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.739446029.793582379 Get It

Beyond Physical Exercise: The Role of Nutrition, Gut Microbiota and Nutraceutical Supplementation in Reducing Age-Related Sarcopenia
Banerjee, Antara , Chabria, Yashna, Hari, Sruthi, Barbagallo, Mario , He, Fang , Radha, Rajesh Kanna Nandagopal , Balakrishnan, Baskar , Marotta, Francesco , Sriramulu, Sushmitha , Catanzaro, Roberto , Pathak, Surajit

Mayo Clinic

Current Aging Science | February 4, 2021 | Volume: 14 | Issue: 2 | Pages: 94-104

10.2174/1874609814666210203090458 | PMID 33535963 Get It

Sarcopenia is a commonly prevalent geriatric condition mainly characterized by progressive loss of the skeletal muscle mass that results in noticeably reduced muscle strength and quality. Most of the geriatric population above 60 years of age are overweight, leading to the accumulation of fat in the muscles resulting in abated muscle function. The increased loss of muscle mass is associated with high rates of disability, poor motility, frailty and mortality. The excessive degeneration of muscles is now also being observed in middle-aged people. Therefore, geriatrics has recently started shifting towards the identification of early stages of the disability in order to expand the life span of the patient and reduce physical dependence. Recent findings have indicated that patients with increased physical activity are also affected by sarcopenia, therefore indicating the role of nutritional supplements to enhance muscle health which in turn helps to counteract sarcopenia. Various interventions with physical training have not provided substantial improvements to this disorder, thereby highlighting the crucial role of nutritional supplementation in enhancing muscle mass and strength. Nutritional supplementation has not only been shown to enhance the positive effects of physical interventions but also have a profound impact on the gut microbiome that has come forward as a key regulator of muscle mass and function. This brief review throws light upon the efficiency of nutrients and nutraceutical supplementation by highlighting their ancillary effects in physical interventions as well as improving the gut microbiome status in sarcopenic adults, thereby giving rise to a multimodal intervention for the treatment of sarcopenia.
68Ga DOTATATE PET/CT imaging of Currarino syndrome with neuroendocrine tumor
Harwood, Matthew L, Nguyen, Ba D. , Nguyen, B D

Mayo Clinic

Japanese Journal of Clinical Oncology | February 4, 2021 | Volume: 51 | Issue: 6 | Pages: 1013-1014

10.1093/jjco/hyab020 | PMID 33621319 Get It

Acute myeloid leukemia after age 70 years: A retrospective comparison of survival following treatment with intensive versus HMA ± venetoclax chemotherapy
Begna, Kebede H. , Gangat, Naseema , Al‐Kali, Aref , Litzow, Mark R. , Patnaik, Mrinal M. , Pardanani, Animesh , Hook, C. Christopher , Wolanskyj, Alexandra P. , Elliott, Michelle A. , Hanson, Curtis A. , Tefferi, Ayalew , Patnaik, Mrinal , Pardanani, Animesh , Elliott, Michelle , Tefferi, Ayalew , Wolanskyj-Spinner, Alexandra P , Hogan, William J. , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | February 4, 2021 | Volume: 96 | Issue: 4 | Pages: No page available

10.1002/ajh.26112 | PMID 33527451 Get It